Affiliation:
1. Department of Applied Life Science, Graduate School, Konkuk University, Chungju 27478, Republic of Korea
2. Research Institute of Inflammatory Disease, Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju 27478, Republic of Korea
3. Nanotechnology Research Center, Konkuk University, Chungju 27478, Republic of Korea
Abstract
Thymoquinone (TQ) is an active ingredient isolated fromNigella sativaand has various pharmacological activities, such as protection against oxidative stress, inflammation, and infections. In addition, it might be a potential neuropharmacological agent because it exhibits versatile potential for attenuating neurological impairments. It features greater beneficial effects in toxin-induced neuroinflammation and neurotoxicity. In various models of neurological disorders, it demonstrates emergent functions, including safeguarding various neurodegenerative diseases and other neurological diseases, such as stroke, schizophrenia, and epilepsy. TQ also has potential effects in trauma mediating and chemical-, radiation-, and drug-induced central nervous system injuries. Considering the pharmacokinetic limitations, research has concentrated on different TQ novel formulations and delivery systems. Here, we visualize the neuropharmacological potential, challenges, and delivery prospects of TQ, specifically focusing on neurological disorders along with its chemistry, pharmacokinetics, and toxicity.
Funder
Ministry of Education, Science and Technology
Subject
Cell Biology,Ageing,General Medicine,Biochemistry
Cited by
64 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献